Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis

Molecular Cancer Therapeutics

Volumn 1, Issue 4, 2002, Pages 275-286

  Yokoi, Akira ^a   Kuromitsu, Junro ^a   Kawai, Takatoshi ^a   Nagasu, Takeshi ^a   Sugi, Naoko Hata ^a   Yoshimatsu, Kentaro ^a   Yoshino, Hiroshi ^a   Owa, Takashi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PRIMER DNA; SULFONAMIDE; TUBULIN; TUMOR PROTEIN;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CHEMISTRY; DNA MICROARRAY; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TRANSCRIPTION, GENETIC; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0036463981     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science (Wash. DC), 287: 1964-1969, 2000. (Pubitemid 30158663)
2. Drews, J. Drug discovery: a historical perspective. Science (Wash. DC), 287: 1960-1964, 2000. (Pubitemid 30158662)
3. Maren, T. H. Relations between structure and biological activity of sulfonamides. Ann. Rev. Pharmacol. Toxicol., 16: 309-327, 1976.
4. Supuran, C. T., and Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents, 10: 575-600, 2000. (Pubitemid 30251754)
5. Yoshino, H., Ueda, N., Niijima, J., Sugumi, H., Kotake, Y., Koyanagi, N., Yoshimatsu, K., Asada, M., Watanabe, T., Nagasu, T., Tsukahara, K., Iijima, A., and Kitoh, K. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem., 35: 2496-2497, 1992.
6. Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi, N. H., Nagasu, T., Koyanagi, N., and Kitoh, K. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem., 42: 3789-3799, 1999. (Pubitemid 29453460)
7. Owa, T., Okauchi, T., Yoshimatsu, K., Sugi, N. H., Ozawa, Y., Nagasu, T., Koyanagi, N., Okabe, T., Kitoh, K., and Yoshino, H. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg. Med. Chem. Lett., 10: 1223-1226, 2000. (Pubitemid 30345096)
8. Owa, T., and Nagasu, T. Novel sulphonamide derivatives for the treatment of cancer. Exp. Opin. Ther. Patents, 10: 1725-1740, 2000.
9. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N., and Kitoh, K. Mechanism of action of E7010: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res., 57: 3208-3213, 1997. (Pubitemid 27351737)
10. Koyanagi, N., Nagasu, T., Fujita, F., Watanabe, T., Tsukahara, K., Funahashi, Y., Fujita, M., Taguchi, T., Yoshino, H., and Kitoh, K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res., 54: 1702-1706, 1994. (Pubitemid 24116173)
11. Yamamoto, K., Noda, K., Yoshimura, A., Fukuoka, M., Furuse, K., and Niitani, H. Phase I study of E7010. Cancer Chemother. Pharmacol., 42: 127-134, 1998. (Pubitemid 28267293)
12. Ozawa, Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi, N., Yoshino, H., Kitoh, K., and Yoshimatsu, K. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur. J. Cancer, 37: 2275-2282, 2001. (Pubitemid 33001300)
13. Punt, C. J., Fumoleau, P., van de Walle, B., Faber, M. N., Ravic, M., and Campone, M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol., 12: 1289-1293, 2001. (Pubitemid 32994759)
14. Punt, C. J. A., Fumoleau, P., Walle, B. V. D., Deporte-Fety, R., Bourcier, C., Faber, M., Ravic, M., and T. Wagener, D. J. Proc. Am. Assoc. Cancer Res., 41: 609, 2000.
15. Raymond, E., ten Bokkel-Huinink, W. W., Taieb, J., Beijnen, J. H., Mekhaldi, S., Kroon, K., Wanders, J., Ravic, M., Fumoleau, P., Ducreux, M., Escudier, B., and Armand, J. P. Proc. Am. Assoc. Cancer Res., 41: 611, 2000.
16. Schena, M., Shalon, D., Davis, R. W., and Brown, P. O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (Wash. DC), 270: 467-470, 1995.
17. Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E. L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol., 14: 1675-1680, 1996. (Pubitemid 26414810)
18. Stockwell, B. R., Hardwick, J. S., Tong, J. K., and Schreiber, S. L. Chemical genetic and genomic approaches reveal a role for copper in specific gene activation. J. Am. Chem. Soc., 121: 10662-10663, 1999.
19. Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., Bassett, D. E., Jr., Hartwell, L. H., Brown, P. O., and Friend, S. H. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med., 4: 1293-1301, 1998. (Pubitemid 28512111)
20. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and Schreiber, S. L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA, 96: 14866-14870, 1999. (Pubitemid 30019731)
21. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O., and Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 24: 236-244, 2000. (Pubitemid 30132190)
22. Dittrich, C., Dumez, H., Calvert, H., Hanauske, A. R., Ravic, M., Faber, M., van Houten, T., Wanders, J., and Fumoleau, P. Proc. Am. Assoc. Cancer Res., 41: 609, 2000.
23. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983. (Pubitemid 14203433)
24. Rödicker, F., Stiewe, T., Zimmermann, S., and Pützer, B. M. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res., 61: 7052-7055, 2001. (Pubitemid 32946495)
25. Liu, X. M., Wang, L. G., Kreis, W., Budman, D. R., and Adams, L. M. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br. J. Cancer, 85: 1403-1411, 2001. (Pubitemid 33081940)
26. Kumar, R., and Korutla, L. Induction of expression of interferon-stimulated gene factor-3 (ISGF-3) proteins by interferons. Exp. Cell Res., 216: 143-148, 1995.
27. Hwang, L. H., and Murray, A. W. A novel yeast screen for mitotic arrest mutants identifies DOC1, a new gene involved in cyclin proteolysis. Mol. Biol. Cell, 8: 1877-1887, 1997. (Pubitemid 27451108)
28. Rosania, G. R., Chang, Y-T., Perez, O., Sutherlin, D., Dong, H., Lockhart, D. J., and Schultz, P. G. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol., 18: 304-308, 2000. (Pubitemid 30159482)
29. Ben-Ze'ev, A., Farmer, S. R., and Penman, S. Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell, 17: 319-325, 1979. (Pubitemid 9230311)
30. Chen, Y., McPhie, D. L., Hirschberg, J., and Neve, R. L. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J. Biol. Chem., 275: 8929-8935, 2000. (Pubitemid 30180250)
31. Nigg, E. A. Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Curr. Opin. Cell Biol., 8: 312-317, 1996. (Pubitemid 26179209)
32. Rossignol, M., Kolb-Cheynel, I., and Egly, J. M. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO J., 16: 1628-1637, 1997. (Pubitemid 27151958)
33. Yankulov, K. Y., and Bentley, D. L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J., 16: 1638-1646, 1997. (Pubitemid 27151959)
34. Araujo, S. J., Tirode, F., Coin, F., Pospiech, H., Syvaoja, J. E., Stucki, M., Hubscher, U., Egly, J. M., and Wood, R. D. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev., 14: 349-359, 2000. (Pubitemid 30106489)
35. Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol., 19: 265-272. 2001. (Pubitemid 32063505)
36. McKendrick, L., Thompson, E., Ferreira, J., Morley, S. J., and Lewis, J. D. Interaction of eukaryotic translation initiation factor 4G with the nuclear cap-binding complex provides a link between nuclear and cytoplasmic functions of the m(7) guanosine cap. Mol. Cell. Biol., 21: 3632-3641, 2001. (Pubitemid 32466977)
37. 2+-dependent transbilayer movement of phospholipid. J. Biol. Chem., 271: 17205-17210, 1996.
38. Kawakami, T., Furukawa, Y., Sudo, K., Saito, H., Takami, S., Takahashi, E., and Nakamura, Y. Isolation and mapping of a human gene (PDCD2) that is highly homologous to Rp8, a rat gene associated with programmed cell death. Cytogenet. Cell Genet., 71: 41-43, 1995.